Roche’s Chugai Sues Alexion to Block Sales of Ultomiris Drug

Roche’s Chugai unit said Alexion’s Ultomiris, used to treat rare life-threatening blood diseases, infringes its patent.

• Roche is seeking cash compensation of “any available damages” and a court order blocking U.S. sales of Ultomiris, according to a complaint filed Tuesday in federal court in Wilmington, Delaware
• Ultomiris is taken every eight weeks, a more convenient dosing than Alexion’s blockbuster Soliris, which is taken every two weeks
  • The drugs are used to treat potentially fatal blood diseases including paroxysmal nocturnal hemoglobinuria (PNH)
• Alexion sells both Soliris and Ultomiris, but makes most of its revenue from Soliris sales, making it ...